A Randomised, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ACV1 in Healthy Adult Male Subjects.
Latest Information Update: 16 Jul 2019
At a glance
- Drugs ACV 1 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors Calzada
- 17 Jun 2016 New trial record